



GLOBAL COLON CANCER ASSOCIATION OPPOSES REFORMS THAT HINDER CANCER RESEARCH

The Global Colon Cancer Association is deeply concerned that drug pricing provisions in the U.S. Senate's budget reconciliation bill could discourage the development of lifesaving oncology treatments.

The proposed price controls would dramatically reduce investment in biopharmaceutical research and development, ultimately resulting in 135 fewer drugs coming to market through 2039, according to a recent study authored by academics at the University of Chicago.

That lost scientific progress would deal a massive blow to one of President Biden's most important, and personal, initiatives -- his "Moonshot" program designed to cure cancer once and for all. There are well over 1,000 cancer drugs currently in early-stage development, including 40 for colorectal cancer alone. Passing these drug pricing provisions could bring many of these early-stage development projects to a halt.

New drugs are key to reducing deaths from cancer, a disease that afflicts almost 40% of Americans at some point in their lives. Advances in treatment account for nearly three-quarters of the recent life-expectancy gains in the war on cancer, according to a University of Southern California study that analyzed cancer outcomes over a 10-year period. There is simply no substitute for research and innovation.

To make matters worse, the bill would do little to assist patients who struggle to afford their medications. The bill would repeal the "rebate rule," which would have required insurers and pharmacy benefit managers to pass manufacturer rebates on to patients at the pharmacy counter.

Reducing drug costs is an admirable goal, but it mustn't be accomplished on the backs of the vulnerable patients. Congress must find another way.

###